BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37923138)

  • 1. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Inhibition of Gα
    Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
    Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
    Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
    Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma.
    Neelature Sriramareddy S; Smalley KSM
    Clin Cancer Res; 2021 Mar; 27(5):1217-1219. PubMed ID: 33355300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
    Gaffal E
    J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
    Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
    Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Oncogenic Gα
    Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
    Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct targeting of Gα
    Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
    Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.